- Report
- February 2026
- 250 Pages
Global
From €4073EUR$4,490USD£3,511GBP
- Report
- February 2026
- 250 Pages
Global
From €4073EUR$4,490USD£3,511GBP
- Report
- July 2026
- 282 Pages
Global
From €5307EUR$5,850USD£4,574GBP
- Report
- September 2025
- 150 Pages
Global
From €4037EUR$4,450USD£3,479GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,133USD£3,122GBP
- Report
- November 2023
- 135 Pages
Global
From €3629EUR$4,000USD£3,128GBP
- Report
- June 2025
- 150 Pages
Global
From €3402EUR$3,750USD£2,932GBP
- Clinical Trials
- April 2025
- 50 Pages
Global
From €1361EUR$1,500USD£1,173GBP
- Report
- December 2024
- 30 Pages
Global
From €2495EUR$2,750USD£2,150GBP
- Report
- September 2024
- 343 Pages
Global
From €7212EUR$7,950USD£6,216GBP
- Report
- July 2024
- 150 Pages
Global
From €3402EUR$3,750USD£2,932GBP
- Report
- June 2025
- 400 Pages
Global
From €4490EUR$4,949USD£3,870GBP
- Report
- March 2023
- 147 Pages
Global
From €4490EUR$4,949USD£3,870GBP
- Report
- May 2024
- 137 Pages
Global
From €3628EUR$3,999USD£3,127GBP
- Report
- April 2023
- 117 Pages
Global
From €4309EUR$4,750USD£3,714GBP
- Report
- January 2023
- 85 Pages
Europe
From €1361EUR$1,500USD£1,173GBP
- Report
- January 2024
- 114 Pages
United States
€3175EUR$3,500USD£2,737GBP
- Report
- January 2024
- 156 Pages
United States
€3447EUR$3,800USD£2,971GBP
- Report
- May 2021
- 50 Pages
China
From €2359EUR$2,600USD£2,033GBP
- Report
- July 2018
- 33 Pages
Global
From €9072EUR$10,000USD£7,819GBP

Tiotropium is a long-acting anticholinergic drug used to treat chronic obstructive pulmonary disease (COPD). It is a bronchodilator, meaning it relaxes the muscles in the airways, allowing more air to flow in and out of the lungs. It is available in both an inhaler and a dry powder inhaler. Tiotropium is the only long-acting anticholinergic approved for the treatment of COPD. It is also used to treat asthma and other respiratory conditions.
Tiotropium is a popular drug in the respiratory drugs market, as it is effective in treating COPD and other respiratory conditions. It is also well-tolerated, with few side effects. It is available in both generic and brand-name forms, making it accessible to a wide range of patients.
Some companies in the Tiotropium market include Boehringer Ingelheim, GlaxoSmithKline, and Novartis. Show Less Read more